Pharma pipelines don’t fail because of science. They fail because of freedom-to-operate.
That’s the uncomfortable truth many teams only learn after a patent landscape review comes back “complicated”—or worse, after a competitor files an injunction.
In …

Beyond the ANDA: How the 505(b)(2) Pathway Can Turn “Copy” Into Competitive Advantage
The generic playbook is familiar: file an ANDA, win on price, and let scale do the rest. But in today’s crowded pharmaceutical landscape—where launch timing, exclusiv…

Pharma IP teams are used to thinking in “years” and “filings.” But in Russia right now, the clock is moving in ways that can quietly—and permanently—change the value of a portfolio.
Here’s the agitation: if your team is still treating Russia patent ter…

Most drug patent portfolios are built for court—then quietly abandoned for strategy.
That’s the gap. And it’s expensive.
In the patent world, “litigation-aware prosecution” isn’t a buzzword—it’s a discipline. It’s the difference between filing patent…

Hospitals are sitting on a quiet competitive advantage—and many are ignoring it.
In the pharmaceutical supply chain, the most valuable “deadline” isn’t a clinical trial milestone or a formulary committee meeting. It’s patent expiration. And the real le…

Most “generic launch forecasts” are guesses. Patent intelligence turns them into a system.
If you’re in pharma strategy, BD, or competitive intelligence, you’ve probably seen the same pattern: someone predicts a generic launch date, the market reacts, …

Most people “mine” the FDA Orange Book for patents. Smart people mine it for people.
If you’re sourcing business development, BD partnerships, licensing opportunities, or even early signals of where innovation is headed, the FDA Orange Book is more tha…

Biotech investors love “pipeline quality.” But portfolio winners are often built on something less glamorous: how you rank projects when capital is scarce and timelines are uncertain.
That’s where two finance concepts—Net Present Value (NPV) and the Pr…

The “patent cliff” isn’t just a pharma problem—it’s a talent problem.
Most people talk about the patent cliff as a revenue event: when exclusivity ends, generic competition moves in, pricing pressure hits, and pipelines get stress-tested. But there’s a…

Stop Overstocking Branded Drugs: The Patent Intelligence Playbook for Wholesalers
Branded drug inventory risk isn’t just a supply-chain problem—it’s a patent-timing problem.
For wholesalers, the pain is familiar: you stock branded products expecting st…